Management of Pediatric Type 2 Diabetes
A Practical Overview of Current Guidelines and Emerging Therapies
DOI:
https://doi.org/10.58931/cdet.2023.1212Abstract
Type 2 Diabetes Mellitus (T2DM) can no longer be considered an adult chronic disease. The diagnosis of pediatric T2DM is based on the laboratory criteria of fasting plasma glucose ≥7.0 mmol/L; 2-hour plasma glucose on a 75 g oral glucose tolerance test (OGTT) ≥11.1 mmol/L; random plasma glucose ≥11.1 mmol/L; or A1c ≥6.5% per Diabetes Canada. It is important to note that these criteria are based on extrapolations from adult data, and have not been specifically validated in youth. The International Society for Pediatric and Adolescent Diabetes (ISPAD) adds that the diagnosis should not be made on these laboratory criteria alone, but should include symptoms of hyperglycemia and negative islet auto-antibodies.
A Canadian national surveillance study of pediatric T2DM completed in 2010, has demonstrated a minimum incidence of youth-onset T2DM of 1.54 per 100,000 children per year with significant regional variation; the highest incidence was 12.45 per 100,000 children per year in Manitoba. Youth-onset T2DM disproportionately affected Canadian children from high-risk ethnic groups, with 44% of new diagnoses occurring in the Indigenous, Asian, African and Caribbean populations.
Over the past twenty years, youth-onset diabetes has been rising. In the United States, according to the SEARCH for Diabetes in Youth Study, there has been an annual increase of 7.1% observed across all age, sex, race and ethnic groups. The COVID-19 pandemic has added further escalation in the incidence of youth-onset worsening disease severity at presentation. New cases in the United States rose by 77.3% in the initial year following the COVID-19 pandemic, vs in the two years pre-pandemic. Furthermore, 21% of youth presented with diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome vs previous estimates of 9% pre-pandemic. The SEARCH for Diabetes in Youth Group projects that the number of youths with T2DM will increase from 28,000 to 48,000 youth today, to 220,000 youth by 2060, with widening racial and ethnic disparities among youth with T2DM
References
Diabetes Canada Clinical Practice Guidelines Expert C, Panagiotopoulos C, Hadjiyannakis S, Henderson M. Type 2 Diabetes in children and adolescents. Can J Diabetes. 2018;42 Suppl 1:S247-S54. DOI: https://doi.org/10.1016/j.jcjd.2017.10.037
Shah AS, Zeitler PS, Wong J, Pena AS, Wicklow B, Arslanian S, Chang N, Fu J, Dabadghao P, Pinhas-Hamiel O, Urakami T. ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents. Pediatric Diabetes. 2022 Nov;23(7):872-902. DOI: https://doi.org/10.1111/pedi.13409
Amed S, Dean HJ, Panagiotopoulos C, Sellers EA, Hadjiyannakis S, Laubscher TA, Dannenbaum D, Shah BR, Booth GL, Hamilton JK. Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children: a prospective national surveillance study. Diabetes Care. 2010 Apr 1;33(4):786-91. DOI: https://doi.org/10.2337/dc09-1013
Rodriquez IM, O’Sullivan KL. Youth-Onset Type 2 Diabetes: Burden of Complications and Socioeconomic Cost. Current Diabetes Reports. 2023 Mar 24:1-9. DOI: https://doi.org/10.1007/s11892-023-01501-7
Magge SN, Wolf RM, Pyle L, Brown EA, Benavides VC, Bianco ME, Chao LC, Cymbaluk A, Balikcioglu PG, Halpin K, Hsia DS. The coronavirus disease 2019 pandemic is associated with a substantial rise in frequency and severity of presentation of youth-onset type 2 diabetes. The Journal of Pediatrics. 2022 Dec 1;251:51-9. DOI: https://doi.org/10.1016/j.jpeds.2022.08.010
Imperatore G, Boyle JP, Thompson TJ, Case D, Dabelea D, Hamman RF, Lawrence JM, Liese AD, Liu LL, Mayer-Davis EJ, Rodriguez BL. Projections of type 1 and type 2 diabetes burden in the US population aged < 20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care. 2012 Dec 1;35(12):2515-20. DOI: https://doi.org/10.2337/dc12-0669
RISE Consortium. Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care. 2018;41(8):1717-25. DOI: https://doi.org/10.1530/ey.16.12.4
TODAY Study Group; Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021;385(5):416-26. DOI: https://doi.org/10.1056/NEJMoa2100165
TODAY Study Group. Development and progression of diabetic retinopathy in adolescents and young adults with type 2 diabetes: results from the TODAY study. Diabetes Care. 2021;45(5):1049-55. DOI: https://doi.org/10.2337/dc21-1072
Dabelea D, Stafford JM, Mayer-Davis EJ, D’Agostino R, Dolan L, Imperatore G, Linder B, Lawrence JM, Marcovina SM, Mottl AK, Black MH; SEARCH for Diabetes in Youth Research Group. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA. 2017 Feb 28;317(8):825-35. DOI: https://doi.org/10.1001/jama.2017.0686
Lawrence JM, Reynolds K, Saydah SH, Mottl A, Pihoker C, Dabelea D, Dolan L, Henkin L, Liese AD, Isom S, Divers J. Demographic correlates of short-term mortality among youth and young adults with youth-onset diabetes diagnosed from 2002 to 2015: the SEARCH for Diabetes in Youth Study. Diabetes Care. 2021 Dec 1;44(12):2691-8. DOI: https://doi.org/10.2337/figshare.16606313
Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002 Jan 1;25(1):89-94. DOI: https://doi.org/10.2337/diacare.25.1.89
Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007;30(4):790-4. DOI: https://doi.org/10.2337/dc06-1554
TODAY Study Group; Zeitler P, Epstein L, Grey M, Hirst K, Kaufman F, et al. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007;8(2):74-87. DOI: https://doi.org/10.1111/j.1399-5448.2007.00237.x
Tamborlane WV, Barrientos-Perez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, et al. Liraglutide in Children and Adolescents with Type 2 Diabetes. N Engl J Med. 2019;381(7):637-46. DOI: https://doi.org/10.1056/NEJMoa1903822
Chadda KR, Cheng TS, Ong KK. GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis. Obes Rev. 2021;22(6):e13177. DOI: https://doi.org/10.1111/obr.13177
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, et al. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023;11(3):169-81. DOI: https://doi.org/10.1016/S2213-8587(22)00387-4
Sam S, Edelstein SL, Arslanian SA, Barengolts E, Buchanan TA, Caprio S, et al. Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2021;44(9):1938-47. DOI: https://doi.org/10.2337/figshare.14368220.v1
Kelsey MM, Zeitler PS, Nadeau KJ, Shah AS. Type 2 diabetes in youth: Rationale for use of off-label antidiabetic agents. Pediatr Diabetes. 2022;23(6):615-9. DOI: https://doi.org/10.1111/pedi.13350
American Diabetes Association Professional Practice Committee. 14. Children and adolescents: Standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S208-S31. DOI: https://doi.org/10.2337/dc22-S014
Salama M, Biggs BK, Creo A, Prissel R, Al Nofal A, Kumar S. Adolescents with Type 2 Diabetes: Overcoming Barriers to Effective Weight Management. Diabetes, Metabolic Syndrome and Obesity. 2023 Dec 31:693-711. DOI: https://doi.org/10.2147/DMSO.S365829
Lee V. The experiences and views of children with type 2 diabetes and their families. Diabetes Care Child Young People. 2020;10:165.
Fung A, Irvine M, Ayub A, Ziabakhsh S, Amed S, Hursh BE. Evaluation of telephone and virtual visits for routine pediatric diabetes care during the COVID-19 pandemic. J Clin Transl Endocrinol. 2020;22:100238. DOI: https://doi.org/10.1016/j.jcte.2020.100238
Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Pérez M, Bismuth E, Dib S, Cho JI, Cox D. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. New England Journal of Medicine. 2022 Aug 4;387(5):433-43. DOI: https://doi.org/10.1056/NEJMoa2204601
Weghuber D, Boberg K, Hesse D, Jeppesen OK, Sorrig R, Kelly AS, et al. Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study. J Comp Eff Res. 2023;12(2):e220187. DOI: https://doi.org/10.2217/cer-2022-0187
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, et al. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol. 2022;10(5):341-50. DOI: https://doi.org/10.1016/S2213-8587(22)00052-3
Li X, Sun T, Du X, Xie X, Shi L. The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review. J Pediatr Endocrinol Metab. 2022;35(12):1457-63. DOI: https://doi.org/10.1515/jpem-2021-0533
Tang Y, Zhang L, Zeng Y, Wang X, Zhang M. Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis. Front Pharmacol. 2022;13:1016639. DOI: https://doi.org/10.3389/fphar.2022.1016639
Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Brandt ML, Xanthakos SA, et al. Five-Year outcomes of gastric bypass in adolescents as compared with adults. N Engl J Med. 2019;380(22):2136-45. DOI: https://doi.org/10.1056/NEJMoa1813909
Pinhas-Hamiel O, Levy-Shraga Y. Eating disorders in adolescents with type 2 and type 1 diabetes. Curr Diab Rep. 2013;13(2):289-97. DOI: https://doi.org/10.1007/s11892-012-0355-7
Racicka E, Brynska A. Eating Disorders in children and adolescents with Type 1 and Type 2 diabetes: prevalence, risk factors, warning signs. Psychiatr Pol. 2015;49(5):1017‑24. DOI: https://doi.org/10.12740/PP/39536
Ercelik ZE, Caglar S. Effectiveness of active video games in overweight and obese adolescents: a systematic review and meta-analysis of randomized controlled trials. Ann Pediatr Endocrinol Metab. 2022;27(2):98-104. DOI: https://doi.org/10.6065/apem.2244036.018
Tang TS, Mahmood B, Amed S, McKay H. Drawing on cultural traditions to improve cardiorespiratory fitness with South Asian children: a feasibility study. Child Obes. 2022;18(5):333-41. DOI: https://doi.org/10.1089/chi.2021.0187
Priya G, Grewal E. When the DHOL is beating, BHANGRA comes to the rescue! Indian J Endocrinol Metab. 2021;25(3):253-4. DOI: https://doi.org/10.4103/ijem.ijem_303_21
Hawkes CP, Lipman TH. Racial disparities in pediatric Type 1 diabetes: yet another consequence of structural racism. Pediatrics. 2021;148(2). DOI: https://doi.org/10.1542/peds.2021-050333
Reid LA, Zheng S, Mendoza JA, Reboussin BA, Roberts AJ, Sauder KA, et al. Household food insecurity and fear of hypoglycemia in adolescents and young adults with diabetes and parents of youth with diabetes. Diabetes Care. 2023;46(2):262-9. DOI: https://doi.org/10.2337/dc21-1807
Egede LE, Campbell JA, Walker RJ, Linde S. Structural racism as an upstream social determinant of diabetes outcomes: a scoping review. Diabetes Care. 2023;46(4):667-77. DOI: https://doi.org/10.2337/dci22-0044
Gulley LD, Shomaker LB. Depression in youth-onset type 2 diabetes. Curr Diab Rep. 2020;20(10):51. DOI: https://doi.org/10.1007/s11892-020-01334-8
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Canadian Diabetes & Endocrinology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
